Abstract
Wastewater is a well-known hotspot for pathogens and spread of antibiotic resistance across species. Surveillance of wastewater microbial community can help draw clearer representation of actively culturing taxonomic groups and resistance-inducing mobile genetic elements before and after treatment. Studies have suggested that COVID-19 pandemic may also have caused increased dissemination of antibiotic-resistance genes (ARGs) and antibiotic-resistant bacteria in wastewater. Although immensely significant, no research has yet been performed on Malaysian wastewater microbial community and ARGs or their correlation with COVID-19 infections. This study utilised 16S metagenomics approach to characterise microbial community in Malaysian wastewater during high and low-case phases of pandemic. Among 20 most prevalent genera around Kuala Lumpur, Malaysia, those belonging to Bacteriodales, Bacillales, Actinomycetales and opportunistic pathogens-Arcobacters, Flavobacteria, and Campylobacterales, Neisseriales, were enriched during high-case periods of the COVID-19 pandemic. Copy number profiling of ARGs in water samples showed prevalence of elements conferring resistance to antibiotics like sulphonamides, cephalosporins, and colistin. High prevalence of intI1 and other ion-based transporters in samples highlight an extensive risk of horizontal gene transfer to previously susceptible species. Our study emphasises the importance of wastewater surveillance in understanding microbial community dynamics and ARG dissemination, particularly during public health crises like the COVID-19 pandemic.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research received no specific grant from funding agencies in the public, commercial, or not-for-profit sectors. MUMGP was supported by a core grant from the School of Science.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The 16S rRNA sequence data that support the findings of this study have been deposited in the Sequence Read Archive (SRA) with the primary accession code PRJNA1095152
